Originally published In Press as doi:10.1074/jbc.M200164200 on March 23, 2002
J. Biol. Chem., Vol. 277, Issue 25, 22768-22780, June 21, 2002
Accelerated Plaque Accumulation, Associative Learning
Deficits, and Up-regulation of
7 Nicotinic Receptor Protein in
Transgenic Mice Co-expressing Mutant Human Presenilin 1 and Amyloid
Precursor Proteins*
Kelly T.
Dineley
§,
Xuefeng
Xia¶,
Duy
Bui
,
J. David
Sweatt
**, and
Hui
Zheng
¶
From the
Division of Neuroscience, the
Department of Molecular Physiology and Biophysics,
¶ Huffington Center on Aging, and the 
Department
of Molecular and Human Genetics, Baylor College of Medicine,
Houston, Texas 77030
Received for publication, January 7, 2002, and in revised form, March 8, 2002
 |
ABSTRACT |
Familial Alzheimer's disease-associated
mutations in presenilin 1 or 2 or amyloid precursor protein result in
elevated
-amyloid,
-amyloid accumulation, and plaque formation in
the brains of affected individuals. By crossing presenilin 1 transgenic
mice carrying the A246E mutation with plaque-producing amyloid
precursor protein K670N/M671L transgenic mice (Tg2576), we show that
co-expression of both mutant transgenes results in acceleration of
amyloid accumulation and associative learning deficits. At 5 months of
age with no detectable plaque pathology, amyloid precursor protein
transgenic animals are impaired in contextual fear learning following
two pairings of conditioned and unconditioned stimuli but appear normal following a more robust five-pairing training. At 9 months of age when
-amyloid deposition is evident, these mice are impaired following
both two-pairing and five-pairing protocols. Mice carrying both
transgenes are impaired in contextual fear conditioning at either age.
All transgenic animal groups performed as well as controls in cued fear
conditioning, indicating that the contextual fear learning deficits are
hippocampus-specific. The associative learning impairments are
coincident with elevated
7 nicotinic acetylcholine receptor protein
in the dentate gyrus. These findings provide two robust and rapid
assays for
-amyloid-associated effects that can be performed on
young animals: impaired contextual fear learning and up-regulation of
7 nicotinic receptors.
 |
INTRODUCTION |
Early on, Alzheimer's disease
(AD)1 presents clinically as
impaired memory formation, yet despite intensive study the mechanisms underlying AD-related memory dysfunction remain mysterious. Familial AD
(FAD) is associated with several risk factors, the best-correlated being age and the inheritance of specific genes (mutations or allele
type) that result in increased
-amyloid (A
) production. The
discovery that soluble A
is elevated in the brains of AD patients
raises the issue whether these molecules play a causative role in AD
(1). A
is generated from the amyloid precursor protein (APP) through
endoproteolytic cleavage by
- and
-secretases (2). In normal
individuals, A
40 comprises the majority of the A
population; a
far smaller fraction is made up of A
42 (1). A
42 is highly
fibrillogenic and exhibits trophic and toxic effects on neurons
(3-5).
Utilizing acute and organotypic hippocampal slice preparations, we have
recently shown that A
42 activates the mitogen-activated protein
kinase (MAPK) cascade through
7 nicotinic acetylcholine receptors
(
7 nAChRs) (6). We also demonstrated that elevation of A
in
vivo using an animal model for AD (Tg2576) (7), leads to the
up-regulation of hippocampal
7 nAChR protein.
7 nAChR up-regulation in the hippocampus of Tg2576 animals negatively correlates with their performance in the Morris water maze, a hippocampus-dependent spatial learning task, and
7 nAChR up-regulation occurs concomitantly with dysregulation of the
42-kDa isoform of extracellular signal-regulated kinase (ERK2) MAPK
(6). Considering that ERK MAPK activity is necessary for rodent spatial
learning,
7 nAChR up-regulation in hippocampus may serve as a
biochemical marker for the synaptic plasticity impairments and learning
and memory deficits in Tg2576 animals (8-10). Our working model posits that hippocampus-dependent learning and memory impairments
in AD arise because of increased A
burden and chronic activation of
the ERK MAPK cascade in hippocampus through
7 nAChRs.
We tested the hypothesis that transgenic animals in which A
is
elevated to varying degrees will exhibit
hippocampus-dependent behavioral impairments. We also
tested whether the cognitive deficits might precede plaque deposition
and coincide with increased
7 nAChR protein in the hippocampus. In
this study, we performed a histopathological, biochemical, and
behavioral characterization of three transgenic mouse lines expressing
mutant human PS-1 (A246E) (11), mutant human APP (K670N/M671L) (7), or
both the mutated human genes that are linked to FAD. We found that
plaque appearance is accelerated in the brains of PS-1/APP transgenic
animals. In addition, the three groups of transgenic animals and
non-transgenic controls were evaluated for behavioral and associative
learning performance at 5 and 9 months of age. Behavioral analyses were followed by biochemical measurement of
7 nAChR levels in CA1 and DG
of the hippocampus. We found an age-dependent decrement in
hippocampus-dependent associative learning. This cognitive defect coincides with elevated
7 nAChR protein in DG. Our data provide evidence that the age-of-onset for behavioral manifestation of
hippocampal dysfunction precedes gross plaque deposition, and
7
nAChR protein level in the hippocampus serves as a biochemical marker
for this defect.
 |
MATERIALS AND METHODS |
Mouse Lines--
To generate the four mouse genotypes used in
this study, heterozygous mutant (K670N/M671L) APP (50% C57B6, 50%
SJL) (7) transgenic mice were crossed with heterozygous mutant (A246E) PS-1 (50% C57B6, 50% SJL) (11) transgenic mice to generate
heterozygous PS-1/APP transgenic mice as well as heterozygous singly
transgenic and wild-type animals. Nomenclature for the transgenic
animal lines is as follows: PS-1 refers to animals heterozygous for the PS-1 A246E transgene; APP refers to animals heterozygous for the APP
K670N/M671L transgene; PS-1/APP refers to animals heterozygous for both
mutant transgenes. Nontransgenic control animals were littermates
generated in the breeding for PS-1/APP transgenic animals. As a control
for the effects of mutant PS-1 on plaque deposition and A
levels,
transgenic animals heterozygous for both human wild-type PS-1 and
mutant PS-1 transgenes were generated. Mouse genotype was determined by
PCR (11). The genetic backgrounds of the mice analyzed were 50% C57B6,
50% SJL. Male and female mice were used. All animal experiments were
performed in accordance with the Baylor College of Medicine
Institutional Animal Care and Use Committee and with national
regulations and policies.
Immunohistochemistry--
Mice were cardiac-perfused with
phosphate buffered saline (10 mM NaHPO4,
150 mM NaCl, pH 7.2) and fixed with 4% paraformaldehyde. Frozen brain sections were sectioned coronally at a 12-µm thickness using a cryostat, mounted on ProbeOn Plus microscope slides (Fisher Scientific), and air-dried. Immediately before staining, the brain sections were fixed with acetone. Tissue sections were incubated for 30 min in 0.3% H2O2 and 0.3% normal goat serum,
washed in phosphate-buffered saline, and incubated with 1.5% normal
goat serum in phosphate-buffered saline for 30 min. Brain sections were
then incubated with anti-A
antibody 6E10 (1:1000, Senetik) stained
with biotinylated anti-mouse IgG (1:200, Vector Laboratories), and
immunodetected with Vectastain ABC Reagent (1:100, Vector Laboratories). Sections were counter-stained with hematoxylin.
Hippocampus Dissection--
Animals were decapitated, and both
hippocampi removed and placed into ice-cold cutting solution (1.25 mM NaH2PO4, 28 mM
NaHCO3, 60 mM NaCl, 3 mM KCl, 110 mM sucrose, 0.5 mM CaCl2, 7 mM MgCl2, 5 mM glucose, 0.6 mM ascorbate). Area CA1 and DG were subdissected from each
hippocampus by trimming away the alveus and fimbria of cross-sections
of ventral hippocampus. CA1 and DG were separated from CA3 by slicing
cross-wise at the lateral aspect of the hippocampal fissure. The slice
was then sectioned through the hippocampal fissure to separate CA1 and
DG. Isolated hippocampal regions were prepared for quantitative
immunoblotting as described.
Quantitative Immunoblotting--
Quantitative immunoblotting was
previously described in Dineley et al. (6). Briefly,
harvested brain tissue was sonicated in sonication buffer (10 mM HEPES, pH7.4, 150 mM NaCl, 50 mM
NaF, 1 mM ED/EGTA, 10 mM
Na4P2O7, 200 nM
calyculin A, 10 µg/ml leupeptin, 2 µg/ml aprotinin, 1 µM microcystin-LR, 1 mM
Na3VO4), and protein concentration was
determined with BCA (Pierce). Samples were subjected to SDS-PAGE,
transferred to Immobilon-P (Millipore), and followed by immunoblot with
the appropriate primary and secondary antibodies and chemiluminescence
(ECL, Amersham Biosciences). Band intensity was quantified with
Scion Image software (NIH Image) from film exposures (BioMax, Kodak) in
the linear range for each antibody and normalized to control level.
Normalized control values were determined for each immunoblot by
averaging control values, dividing each control and transgenic sample
density by the average of the control set, and then determining the
average and standard error of the mean (S.E.) for control and
transgenic samples: 5 months, n = 9 control animals,
n = 6 PS-1, n = 15 APP, and
n = 10 PS-1/APP transgenic animals; 9 months,
n = 14 control animals, n = 5 PS-1, n = 11 APP, and n = 11 PS-1/APP
transgenic animals.
Open Field Test--
Each subject was placed into the center of
an open field chamber, a clear arena 43 × 43 cm in dimension
illuminated by a 75-W bulb. The open field was divided into 225 equally
sized squares by 15 photoreceptor beams on each side of the arena.
Locomotor activity was quantified using a Digiscan optical animal
activity system (RXYZCM, Accuscan Electronics) (16). Activity measures represent the number of photoreceptor beam breaks in both the horizontal and vertical planes collected in 2-min intervals over a
30-min test period. Additional activity data include the total distance
traveled in the horizontal plane (in cm) and the ratio of the time
spent in the 16 most centrally located squares compared with the total
distance traveled (center:distance ratio): 5 months, n = 11 control animals, n = 6 PS-1, n = 19 APP, and n = 12 PS-1/APP transgenic animals; 9 months, n = 11 control animals, n = 9 PS-1, n = 15 APP, and n = 9 PS-1/APP
transgenic animals.
Rotarod Test--
Motor coordination, balance, and motor
learning were evaluated with the accelerating rotarod test. In this
test, mice were assessed for their ability to maintain their balance on
a rotating bar that accelerates 7.2 rpm/min. Over the course of each
5-min trial, the speed of the rotarod accelerated from 4 to 40 rpm. The
amount of time before the subject fell from the rod was measured. Mice
underwent four rotarod trials per day for two consecutive days with an
intertrial interval of no less than 30 min: 5 months, n = 10 control animals, n = 6 PS-1, n = 18 APP, and n = 11 PS-1/APP transgenic animals; 9 months, n = 11 control animals, n = 9 PS-1, n = 14 APP, and n = 7 PS-1/APP
transgenic animals.
Shock Threshold--
Sensory perception of the shock used in
fear conditioning was determined through shock threshold assessment. A
sequence of single foot shocks was delivered to animals placed on the
same electrified grid used for fear conditioning. Initially, a 0.1-mV shock was delivered for 1 s, and the animals' behavior was
evaluated for flinching, jumping, and vocalization. At 30-s intervals
the shock intensity was increase by 0.1 mV up to 0.7 mV and then
returned to 0 mV in 0.1-mV increments at 30-s intervals. Threshold to
vocalization, flinching, and then jumping was quantified for each
animal by averaging the shock intensity at which each animal manifested a behavioral response to the foot shock: 9 months, n = 11 control animals, n = 6 PS-1, n = 4 APP, and n = 5 PS-1/APP transgenic animals.
Fear Conditioning and Assessing Conditioned Fear-tested
Associative Learning--
First, with a two-pairing paradigm of cue
and mild foot shock, animals were placed in the fear conditioning
apparatus for a total of 7 min. Animals were left free to explore for 3 min, and then a 30-s acoustic-conditioned stimulus (CS; white noise, 80 dB) was delivered. At the end of the CS, a 2-s shock unconditioned stimulus (US; 0.5 mA) was applied to the grid floor. The CS-US pairing
was delivered again at the 5-min mark. To evaluate contextual fear
learning, the animals were returned to the training context 24 h
posttraining, and freezing behavior was scored for 5 min. To evaluate
cued fear learning, the animals were placed in a different context
(novel odor, lighting, cage floor, and visual cues) following contextual testing. Baseline behavior was scored for 3 min, and then
the CS was presented for a period of 3 min. Freezing behavior was
scored as follows: each animal was observed for ~1 s every 5 s
and judged to be freezing or not by postural criteria. Data is
expressed as percent freezing in 30- or 60-s epochs, each epoch divided
into 6 or 12 5-s bins. The experimenter was blind to the genotype of
the subjects. No less than six animals of each genotype were tested per group.
For the five-pairing paradigm, 20-s acoustic CS-US pairings were given
five times. There was a 40-s interval between each CS-US pairing. All
other aspects of this protocol were the same as in the two-pairing paradigm.
 |
RESULTS |
To produce mice of the desired genotypes, APP K670N/M671L
transgenic mice (7) were crossed with PS-1 transgenic mice containing the A246E FAD mutation (11). Nomenclature for the transgenic animal
lines is as follows: PS-1 refers to animals heterozygous for the PS-1
A246E transgene; APP refers to animals heterozygous for the APP
K670N/M671L transgene; and PS-1/APP refers to animals heterozygous for
both mutant transgenes. Nontransgenic control animals were littermates
generated in the breeding for PS-1/APP transgenic animals. Mice
heterozygous for the following genotypes were generated at equal
ratios: wild-type, PS-1 or APP single transgenic, and PS-1/APP double
transgenic. APP and PS-1/APP mice were subjected to immunohistological
analysis at various ages using the anti-human A
monoclonal antibody
6E10 to visualize plaques (Fig. 1). We
estimate that, with our methodology, we can detect plaques >5 µm in
diameter. At all ages examined, both the density and the size of
plaques in PS-1/APP mice exceeded that of APP mice at comparable ages.
Plaque deposition pattern for PS-1/APP mice was similar to that
reported for the APP mice from which they were generated (7, 12, 13).
Plaques were first observed in cortical regions, followed by
hippocampus.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 1.
PS-1 A246E FAD mutant transgene
greatly accelerates amyloid plaque pathology of the APP transgenic
mice. Brain sections of transgenic mice co-expressing APP
K670N/M671L and PS-1 A246E FAD mutant transgenes were immunostained
with A -specific monoclonal antibody 6E10 and compared with that of
age-matched APP transgenic animals. The top panels are
frontal cortex of mice 7, 9, and 13 months of age, respectively, and
lower panels are mainly hippocampus of mice 7, 9, and 13 months of age, respectively. Scale bars: 50 µm.
|
|
Plaques were not detected in any group at five months of age (data not
shown).
-amyloid plaques were consistently detected in the neocortex
of 7-month-old PS-1/APP transgenic mice when APP transgenic mice were
free of plaques (Fig. 1). At nine months of age, although APP
transgenic mice exhibit occasional A
plaques in the cortex, positive
staining cannot be detected in the hippocampus. At this age, however,
PS-1/APP transgenic mice show numerous A
deposits in various regions
of the brain, including neocortex and hippocampus (Fig. 1). Plaque
deposits were further enhanced in 13-month-old PS-1/APP mice; multiple
brain areas were covered with plaques (Fig. 1). Littermates that
express PS-1 A246E alone do not develop detectable amyloid plaques up
to 24 months of age, and the wild-type human PS-1 transgene does not
facilitate plaque deposition in mice when co-expressed with the mutant
APP transgene (data not shown).
Having seen differences in A
load and deposition rates between the
various transgenic animals, we wanted to determine whether there were
any cognitive correlates of plaque deposition. Behavioral characterization of non-transgenic control mice and APP, PS-1, or
PS-1/APP transgenic mouse lines included the open field test, rotarod
test, and an associative learning test, fear conditioning. In addition,
each group of mice was subjected to a general health assessment and
evaluated for normal sensory processing. As reported in previous
studies, the APP and PS-1 animals exhibited no apparent differences in
general health from control animals (7, 11, 14). Similarly, differences
in general health between PS-1/APP mice and singly transgenic or
control animals were undetectable.
Open Field--
PS-1, APP, PS-1/APP, and control mice were
monitored in the open field test to evaluate locomotor activity and
anxiety-related behavior. Each animal's movements in both the
horizontal and vertical planes were recorded and quantified. Open field
data can be used to evaluate a mouse's anxiety-related response to
being in a novel, well lit, and unsheltered area by calculating the
ratio between the amount of time spent in the center of the open field
and the total distance traveled during the 30-min observation period. In a brightly lit open area, mice will tend to stay near the walls of
the open field rather than enter the center region; more so for highly
anxious rodents. Genotype had no significant effect on locomotor
activity at any of the ages tested (5 or 9 months of age). One-way
ANOVA revealed no significant effect of genotype on total distance
traveled, number of vertical rearings, time spent in the center of the
grid, or in the center:distance ratio during the 30-min evaluation time
(Table I). We conclude from these
observations that PS-1, APP, or PS-1/APP animals are not abnormally
active in the open field test, nor do they exhibit anomalous
anxiety-related behavior.
View this table:
[in this window]
[in a new window]
|
Table I
Summary of open field test results
For each genotypic group of 5- and 9-month-old animals, total distance
traveled (cm × 100), number of vertical rearings, amount of time
spent in the center of the observation grid, and center: distance ratio
are reported. Values below the mean value represent S.E.
|
|
Rotarod--
The motor abilities of PS-1, APP, PS-1/APP, and
control mice were probed using the rotarod test. The amount of time an
animal can remain on an accelerating rotating wheel is an index of the animal's motor coordination. In addition, it is expected that the
animals gain proficiency in the task with increasing trial number, and
this is taken as an indication of motor learning. As anticipated, each
animal group remained on the rotarod for longer periods of time with
increasing trial number over the course of two training days: 5 months,
F(7,312) = 7.87, p <0.0001; 9 months, F(7, 296) = 25.08, p <0.0001 (Fig.
2). Two-way ANOVA with repeated measures
did not detect an interaction between genotype and trial number,
demonstrating that all groups of mice learned the task at similar
rates. Although the 9-month-old APP and PS-1/APP animals appeared to
plateau in their performance at a lower total time spent on the
rotarod, this effect was not statistically significant. Overall, these
data indicate that PS-1, APP, and PS-1/APP mice are unimpaired in motor
coordination and motor learning as compared with control animals.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 2.
All genotypic groups learn the rotarod
task. Control, PS-1, APP, and PS-1/APP transgenic animals were
placed on the rotarod apparatus for four trials over two consecutive
days. With trial number and days of training, each animal group
increased the amount of time they remained on the rotarod
apparatus.
|
|
Shock Threshold--
After all other behavioral tests were
complete a subset of 9-month-old animals was evaluated for their
ability to perceive shock stimuli. The shock threshold to flinch (Fig.
3a), to jump (Fig.
3b), and to vocalize (Fig. 3c) was quantified for
each animal group. One-way ANOVA and Tukey post hoc analysis did not
detect any significant differences between any of the genotypes except between the PS-1 transgenic and PS-1/APP transgenic animals in their
threshold to vocalize (F(3,22) = 4.11, p < 0.05; Fig. 3). The implications of this difference
are unclear. On the whole, transgenic animals do not appear to be
impaired in their ability to detect mild foot-shock.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 3.
Shock Threshold is similar for all genotypic
groups. Shock intensity threshold to flinch (a), jump
(b), and vocalize (c) was measured for control,
PS-1, APP, and PS-1/APP transgenic animals. No significant differences
were detected for any of the parameters measured except vocalization
threshold for PS-1 versus PS-1/APP transgenic; see
"Results" for p value.
|
|
Associative Learning--
Although no differences in baseline
motor and sensory behaviors were detected between each genotypic group
of mice, we sought to determine whether there might be defects in
higher order cognitive function. A well defined cognitive deficit is
both a hallmark of human AD and an important component of valid animal
models of AD. Thus far, learning and memory impairments described for various transgenic animal models of AD have been detected with behavioral tasks that require multiple days of training and testing (7,
14, 15, 35). We investigated the use of the fear conditioning
associative learning paradigm in our mouse models of AD to potentially
develop a rapid cognition assay for application in these systems.
Fear conditioning is associative and comes in two forms: one that is
hippocampus-dependent (contextual fear learning) and one
that is hippocampus-independent (cued fear learning) (16-20). We chose
this learning paradigm because we can probe cognitive function with a
single training day followed in 24 h by tests for
contextual and cued fear learning, each requiring just minutes to
perform. Most relevant, contextual fear learning is dependent upon a
brain area that has been implicated as a locus for cognitive decline in
AD, the hippocampus.
PS-1, APP, PS-1/AP, and control mice were subjected to a standard fear
conditioning paradigm in which the animals learn to associate neutral
stimuli with an aversive one. The mice were placed in a novel context
(fear conditioning box) and exposed to two pairings of a white noise
cue and mild foot shock. Fear learning was assessed 24 h later by
measuring freezing behavior in response to representation of the
context or of the auditory cue within a completely different context.
At 5 months of age, there were no apparent differences in the
freezing behavior of the different mouse genotypes during the two-pairing training phase of fear conditioning (Fig.
4a). In the contextual test
for fear learning, the APP and PS-1/APP animals exhibited decreased
freezing behavior compared with both the control and PS-1 groups (Figs.
4b, 8a). Two-way ANOVA with repeated measures did
not detect a significant interaction between genotype and time spent in
the context, demonstrating that time spent in the context did not
differentially influence a genotypic group of mice. One-way ANOVA and
Tukey post hoc analysis detected a significant difference in freezing
behavior at the 1-4-min time epochs compared with controls and at the
1-, 2-, 3-, and 5-min epochs compared with the PS-1 group (Fig.
4b; min 1: F(3,60) = 5.60; min 2:
F = 7.68; min 3: F = 8.51; min 4:
F = 4.26; min 5: F = 4.35;
p < 0.05 all groups). Analysis of total freezing
behavior indicates that APP and PS-1/APP animals freeze significantly
less than control and PS-1 animals (see Fig. 9a; Tukey's
multiple comparison test: F(5,16) = 27.97; control
versus APP, control versus PS-1/APP, APP
versus PS-1, PS-1/APP versus PS-1, all
p < 0.001). Thus we conclude that APP and PS-1/APP
animals have a deficit in contextual fear learning as measured by
percent freezing during 1-min bins as well as measured by percent
freezing during the entire observation period.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 4.
5-month-old APP and PS-1/APP transgenic mice
are impaired in contextual fear learning. Two pairings of CS-US
for fear conditioning (a) is followed 24 h later by
testing for contextual (b) and cued (c) fear
learning. # indicates statistically significant difference from
control; * indicates statistically significant difference from PS-1
transgenic animal group; see "Results" for p
values.
|
|
One-way ANOVA and Tukey post hoc analysis determined that all animals
displayed similar and significant freezing in the cued test for
associative learning, indicating that the impairment in contextual fear
learning exhibited by the APP and PS-1/APP animal groups is not due to
an inability to freeze or to an inability to detect the aversive foot
shock stimulus (Fig. 4c; p < 0.001, all
groups; also see "Shock Threshold" above). Therefore, 5-month-old APP and PS-1/APP mice appear to have a selective
hippocampus-dependent impairment in associative learning
following two pairings of conditioned and unconditioned stimuli for
fear conditioning.
We then determined whether a more vigorous training paradigm could
rescue the contextual fear learning impairment in the APP and PS-1/APP
animals. One week later, the four groups of animals were subjected to a
five-pairing fear conditioning training paradigm (Fig.
5a). Statistical analysis of
the freezing exhibited during the first 2 min of the five-pairing
training protocol indicates that control and PS-1 animals' freezing
during this time period is significantly greater than during the first
3 min of two-pairing training 1 week prior when the mice were
naïve (one-way ANOVA and Tukey post hoc analysis
p < 0.01). This result is indicative of the animals'
memory of the context.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 5.
5-month-old APP transgenic mice contextual
fear learning impairment is rescued by a five-pairing training
protocol. Five pairings of CS-US (a) lead to contextual
fear learning (b) in APP transgenic animals that is
indistinguishable from control and PS-1 transgenic animals. PS-1/APP
transgenic mice are still impaired in the contextual test for fear
learning. All genotypic groups learn to freeze upon presentation of the
CS (cue) in the cued test for fear learning (c).
* indicates that APP transgenic animals froze statistically significant
difference from PS-1/APP transgenic animals; see "Results" for
p values.
|
|
Twenty-four hours following training, the animals were tested for
contextual and cued fear learning. Two-way ANOVA with repeated measures
did not detect a significant interaction between genotype and time
spent in the context, demonstrating that time spent in the context did
not differentially influence a genotypic group of mice. Again, the
control and PS-1 mice performed comparably on the contextual fear
learning test (Figs. 5b, 8b). Although the
PS-1/APP mice were still impaired, the APP mice exhibited contextual
fear learning indistinguishable from control and PS-1 mice. Analysis of
total freezing behavior signifies that control, PS-1, and APP animals
freeze significantly more than PS-1/APP transgenic animals (see Fig.
8b; one-way ANOVA and Tukey's multiple comparison test:
F(3,16) = 7.04; all p < 0.05).
Statistical analysis of the 1-min epoch data (unpaired t
test with Welch's correction for significantly different variance)
determined that APP mice performed contextual fear learning
significantly better than PS-1/APP mice (Fig. 5b; min 3: APP
versus PS-1/APP p < 0.03, df = 9; min 5: APP versus PS-1/APP
p < 0.04, df = 16). As before, all
animal groups exhibited significant cued fear learning indicating no general impairment in amygdala function or the type of sensory processing necessary for fear learning (Fig. 5c; one-way
ANOVA p < 0.001, all groups). Thus, this impairment in
contextual fear learning is again suggestive of a hippocampus-specific
behavioral defect.
A separate group of animals 9 months of age were subjected to an
identical fear conditioning paradigm to test for an
age-dependent decline in the contextual fear learning
exhibited by the APP and PS-1/APP animals. Two-way ANOVA with repeated
measures did not detect a significant interaction between genotype and
time spent in the context, demonstrating that time spent in the context
did not differentially influence a genotypic group of mice. Once again, one-way ANOVA detected no significant differences in the levels of
freezing displayed by any of the animal groups during training (Fig.
6a). Control and PS-1 animal
groups did not perform significantly different from each other in the
contextual test for fear learning (Figs. 6b, 8c).
APP and PS-1/APP mice were significantly impaired in the contextual
fear learning test compared with control and PS-1 animals (Fig.
8c; Tukey's multiple comparison test:
F(3,16) = 37.12; control versus APP, control
versus PS-1/APP, PS-1 versus APP, PS-1
versus PS-1/APP, all p < 0.001). When
evaluating 1-min epoch data, APP and PS-1/APP animals froze in the
contextual test significantly less than control animals in epochs 1-3
(Fig. 6b; one-way ANOVA; min 1: F(3,37) = 4.73, p < 0.05; min 2: F = 5.15, p < 0.05; min 3: F = 4.38, p < 0.05). All animal groups exhibited significant
cued fear learning (Fig. 6c; one-way ANOVA;
p < 0.001, all groups).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
9-month-old APP and PS-1/APP transgenic
animals are impaired in contextual fear learning. Two pairings of
CS-US for fear conditioning (a) is followed 24 h later
by testing for contextual (b) and cued (c) fear
learning. Cued fear learning was comparable for all genotypic groups. *
indicates a statistically significant difference from both control and
PS-1 transgenic animal groups; see "Results" for p
values.
|
|
When animals were tested for contextual fear learning 24 h after
five pairings of CS-US, two-way ANOVA with repeated measures did not
detect a significant interaction between genotype and time spent in the
context, demonstrating that time spent in the context did not
differentially influence a genotypic group of mice. Control and PS-1
transgenic animal groups once again did not perform significantly
different from each other in the contextual test for fear learning.
When assessing total freezing levels, APP and PS-1/APP transgenic
animals displayed abnormal freezing behavior as compared with control
and PS-1 transgenic animals (see Fig. 8d; Tukey's multiple
comparison test: F(3,16) = 20.21; control
versus APP, control versus PS-1/APP, PS-1
versus APP, PS-1 versus PS-1/APP, all
p < 0.05). Both APP and PS-1/APP animals' freezing
behavior was significantly different from control animals at the second
1-min epoch (Fig.
7b;
one-way ANOVA; F(3,37) = 10.36, p < 0.05) and APP animals' freezing behavior was significantly different
from control animals at every epoch (Fig. 7b; one-way ANOVA;
min 1: F = 6.09, p < 0.01; min 3:
F = 7.98, p < 0.001; min 4:
F = 3.48, p < 0.05; min 5:
F = 5.71, p < 0.05). In other words,
at 9 months of age, the more robust five pairings of CS-US failed to
rescue the contextual fear-learning impairment exhibited by APP animals
following two pairings of CS-US. To test for an age-dependent decline in APP animals' performance from 5 to 9 months of age, statistical analysis of total freezing following five pairings of CS-US was performed. Two-way ANOVA detected a significant interaction of age and genotype for performance in the
contextual test at 5 and 9 months of age following five-pairing training (p < 0.0001). Tukey post hoc analysis
indicates that APP animals' performance in the contextual test
significantly declined from 5 to 9 months of age following training
with the five-pairing protocol (one-way ANOVA; F(7,32) = 12.20 p < 0.001). None of the other animal groups
showed significant changes in performance between 5 and 9 months of
age. Therefore, APP transgenic animals' performance in contextual fear
learning declines in an age-dependent manner.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 7.
9-month-old APP transgenic mice exhibit an
age-dependent decline in contextual fear learning.
Five pairings of CS-US (a) lead to contextual (b)
fear learning in control and PS-1 transgenic mice. APP and PS-1/APP
transgenic animals exhibit less freezing in the contextual test of fear
learning. All genotypic groups learn to freeze upon presentation of the
CS (cue) in the cued test for fear learning (c).
* indicates a statistically significant difference from both control
and PS-1 transgenic animal groups; see "Results" for p
values.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 8.
APP and PS-1/APP transgenic animals exhibit
less overall freezing in the contextual test of fear learning following
two pairs of CS-US at 5 months (a) and 9 months
(b) of age. The contextual fear learning impairment in
5-month-old APP transgenic animals is rescued by five pairings of CS-US
(c), whereas this fails to rescue the deficit in 9-month-old
animals (d). * indicates a statistically significant
difference from both control and PS-1 transgenic animal groups; see
"Results" for p values.
|
|
As a control, we tested 2-month-old APP (n = 10),
PS-1/APP (n = 10), and control (n = 15)
animals for contextual fear learning. The three genotypic sets of
animals, 2 months of age, were subjected to two pairs of CS-US and
tested for contextual fear learning 24 h later. None of the animal
groups performed significantly different from any other animal group in
the contextual test for fear learning following the two-pairing
training protocol (one-way ANOVA with Tukey post hoc analysis, results
not shown). Furthermore, all three groups demonstrated significant
contextual fear learning; each animals' freezing performance in the
contextual test was significantly different from the pretraining
baseline (all groups p < 0.005, Student's
t test). These results indicate that 2-month-old animals
acquire contextual fear conditioning and suggest that our findings in
the older animals are not due to overexpression of the transgene or
position effects.
7 nAChR Quantification--
We have previously observed an
age-dependent up-regulation of
7 nAChR protein in the
hippocampi of APP animals (6). Following behavioral assessment of each
animal, their hippocampi were removed and subjected to quantitative
immunoblot to measure
7 nAChR protein levels in area CA1 and DG.
Consistent with our previous findings, the DG of 5-month-old APP
animals had significantly elevated
7 nAChR protein (Fig.
9b; p < 0.003, df = 15; unpaired t test with Welch's correction because the genotype variances were significantly different). PS-1/APP animals, however, had increased
7 nAChR levels
in both area CA1 and DG at 5 months of age (Fig. 9, a and b; p < 0.003 and < 0.006, respectively, df = 11). No significant changes in
7
nAChR levels were detected between 5 and 9 months of age. Again at 9 months of age,
7 nAChR protein was elevated in DG of APP animals
(p < 0.05, df = 13) and in both CA1
and DG of PS-1/APP animals (Fig. 9, c and d;
p < 0.05, df = 10). Overall, our data
indicate an increased expression of
7 nAChR protein in the
hippocampal formation of both the APP and PS-1/APP animals.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 9.
7 nAChR protein level is
elevated in the hippocampus of APP and PS-1/APP transgenic
animals. Quantitative immunoblot for 7 nAChR protein was
performed on CA1 and DG homogenates from the three groups of transgenic
animals and compared with control animals. a, CA1,
5-month-old animals; b, DG 5-month-old animals;
c, CA1 9-month-old animals; d, DG 9-month-old
animals. * indicates a statistically significant difference from
normalized control animals value; see "Results" for p
values.
|
|
PS-1 transgenic animals produce slightly higher amounts of A
compared with animals expressing the wild-type PS-1 transgene and do
not show signs of plaque deposition up to 24 months of age. 5-month-old
PS-1 animals exhibited a significant reduction in
7 nAChR
protein in DG (Fig. 9b; p < 0.001, df = 14). However, from all behavioral parameters
tested, these animals perform comparable with control animals.
Apparently, reduced
7 nAChR expression has no discernable effect on
animal behavior. This is not a surprising finding; behavioral
assessment of
7 nAChR null mice, which included fear conditioning,
failed to detect any behavioral abnormalities (21). By 9 months of age,
a significant reduction in
7 nAChR protein was no longer detected in
the DG of PS-1 animals, possibly indicating a trend toward increased
7 nAChR protein at older ages (Fig 9d).
 |
DISCUSSION |
In this work, we have taken a genetic approach to study the
effects of different A
loads by crossing mice transgenic for PS-1
A246E FAD mutation with animals transgenic for the APP K670N/M671L FAD
mutation. We tested the hypothesis that the combination of FAD
mutations in PS-1/APP animals would lead to an acceleration of amyloid
deposition by performing an immunohistochemical analysis of these
animals at various ages. We have shown that the co-expression of mutant
human APP and mutant human PS-1, but not the wild-type PS-1,
facilitates deposition of amyloid by several months as compared with
APP mice. The plaque deposition pattern in the PS-1/APP animals is
characteristic of the plaques detected in the APP animals (7, 12, 13).
Largely, our data agree well with similar studies reported for mice
expressing different combinations of APP and PS-1 transgenes in that
plaque deposition is accelerated and the pattern of deposition is
similar to that found in the APP singly transgenic animals from which
they are derived (22, 23).
It is now well established that impairment in the encoding of new
episodic memories is typical of the earliest stages of AD (24-26).
Converging lines of evidence have linked the early loss of episodic
memory in AD to medial temporal pathology including the hippocampus
(27-29). In the work described here, we have identified a
hippocampus-dependent associative learning impairment that
manifests itself relatively early in the animals' lifetime, precedes
detectable (plaques > 5 µm) plaque deposition in the
hippocampus and coincides with increased
7 nAChR protein. These
findings and the recent reports by Chishti et al. (15),
Koistinaho et al. (35), and Westerman et al. (36)
describe the earliest yet behavioral and biochemical phenotypes for an
AD mouse model. In addition, the robust impairment in contextual fear
conditioning detected in these transgenic mice provides a simple
and rapid behavioral screen to evaluate potential therapeutic compounds
in rodent models of AD.
No significant differences were detected between PS-1, APP, or PS-1/APP
and control animals when assessed regarding general health, shock
threshold, locomotor activity, motor coordination, and motor learning.
Neither did we observe any deficits in cued fear conditioning; however,
there were significant findings when the animals were evaluated for
contextual fear learning. An impairment in contextual but not in cued
fear learning demonstrates that these animals are capable of freezing,
and indicates that they do not suffer general cortical or amygdala
damage or alterations in sensory processing required for fear learning.
These findings suggest that the impairment in contextual fear learning
is localized to the hippocampus (16-20). Furthermore, we did not
detect impairment in any genotypic set of 2-month-old animals in the
contextual test 24 h following fear conditioning. Thus
demonstrating that the cognitive deficits detected at later ages in the
APP and PS-1/APP transgenic animals is not a consequence of transgene
overexpression or position effects.
APP transgenic animals exhibit a contextual fear learning deficit
24 h after two pairings of CS-US. At this age, APP transgenic animals express significantly higher levels of
7 nAChR protein in
the DG of hippocampus. These findings are consistent with our model
that chronic elevated A
leads to up-regulation of
7 nAChR protein
in hippocampus by interacting with these receptors in hippocampus. This
contextual fear learning impairment is rescued by performing a more
robust training paradigm of five pairings of CS-US. At 9-months of age,
the contextual fear learning deficit in APP animals is no longer
rescued by five pairings of CS-US, indicative of an
age-dependent decline in hippocampus function. At this age,
the level of
7 nAChR protein had not significantly changed from the
level measured at 5 months of age, indicating that the contextual fear
learning impairment that is no longer rescued by five pairings of CS-US
cannot be attributed to accumulating
7 nAChR protein. How
7 nAChR protein accumulation, A
production, and metabolism,
accumulation, and deposition into plaques result in hippocampus
dysfunction and age-related hippocampus-dependent behavioral impairments remains unclear. Possibly, changes in the level
of
7 nAChR protein occur at a different rate than the functional consequences of chronic exposure to A
(30-33). Alternatively, the
increase in
7 nAChR protein could occur independently of hippocampus
dysfunction and impaired associative learning. Future studies examining
the role of
7 nAChR function in hippocampal synaptic plasticity in
these animals at different ages may begin to elucidate a mechanism.
Animals that express both PS-1 and APP transgenes have further
elevation of A
, which apparently accelerates plaque pathology by
several months; plaque deposition evident at 6 months of age in
PS-1/APP mice is not detected to comparable level in APP animals until
9-10 months of age. PS-1/APP animals are impaired in contextual fear
learning and have elevated
7 nAChR protein in both CA1 and DG of the
hippocampus at 5 months of age. At this age, five pairs of CS-US do not
rescue the contextual fear learning impairment exhibited by these mice.
The different age-of-onset for the contextual fear learning deficit in
APP versus PS-1/APP mice suggests that the phenotype is
relevant to the overexpression of A
rather than a feature
contributed by either strain of mice.
In previous studies, we found that A
42 couples via
7 nAChRs to
the MAPK cascade, a critical element in hippocampal synaptic plasticity
and learning (8-10, 34). We also showed that in vivo elevation of A
, such as that exhibited by the APP and PS-1/APP animals used in this study, leads to the up-regulation of
7 nAChR protein in an age-dependent manner (6).
7 nAChR
up-regulation occurs concomitantly with the dysregulation of ERK2 MAPK
in DG of 4-month-old APP animals. ERK MAPK activity is known to be
required for contextual fear learning; therefore, a model we have
previously proposed that is consistent with our current
findings is that hippocampus-dependent
learning and memory impairments in early AD arise in part
because of increases in A
burden and chronic activation of the ERK
MAPK cascade in hippocampus through
7 nAChRs (6, 8, 34).
The work described here identifies a cognitive deficit in two animal
models of AD that localizes to impaired hippocampal function. The
extent of contextual fear learning deficits appears to correlate with
A
production, as it is more pronounced in the PS-1/APP animals. In
AD, the hippocampus is a locus for the earliest stages of impaired memory formation, and our findings that both APP and PS-1/APP animals
exhibit impaired associative learning prior to frank plaque deposition
may be relevant to early human AD. In addition, we may have identified
a biochemical marker that is indicative of hippocampal dysfunction:
7 nAChR up-regulation. These findings of early onset behavioral and
biochemical markers may prove useful in screening new therapies for
AD.
 |
FOOTNOTES |
*
This work was supported by NINDS National Institutes
of Health and Alzheimer's Association awards (to H. Z.), NIA and
NARSAD National Institutes of Health awards and a National Institute of
Mental Health award (to J. D. S.), the Texas Advanced Technology Program and NIA and NRSA National Institutes of Health awards (to
K. T. D.), and an NINDS National Institutes of Health award (to
J. W.P.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence may be addressed: Div. of Neuroscience, Rm.
S603, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. Tel.: 713-798-3107; Fax: 713-798-3946; E-mail:
kdineley@cns.bcm.tmc.edu.
**
To whom correspondence may be addressed: Div. of Neuroscience, Rm.
S603, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. Tel.: 713-798-3107; Fax: 713-798-3946; E-mail:
jsweatt@cns.bcm.tmc.edu.
Published, JBC Papers in Press, March 23, 2002, DOI 10.1074/jbc.M200164200
 |
ABBREVIATIONS |
The abbreviations used are:
AD, Alzheimer's
disease;
FAD, familial AD;
A
,
-amyloid;
APP, amyloid precursor
protein;
MAPK, mitogen-activated protein kinase;
ERK, extracellular
signal-regulated kinase;
DG, dentate gyrus;
CS, conditioned
stimulus;
US, unconditioned stimulus;
ANOVA, analysis of variance;
df, degrees of freedom.
 |
REFERENCES |
| 1.
|
Kuo, Y. M.,
Emmerling, M. R.,
Vigo-Pelfrey, C.,
Kasunic, T. C.,
Kirkpatrick, J. B.,
Murdoch, G. H.,
Ball, M. J.,
and Roher, A. E.
(1996)
J. Biol. Chem.
271,
4077-4081[Abstract/Free Full Text]
|
| 2.
|
Selkoe, D. J.
(1998)
Trends Cell Biol.
8,
447-453[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Lambert, M. P.,
Barlow, A. K.,
Chromy, B. A.,
Edwards, C.,
Freed, R.,
Liosatos, M.,
Morgan, T. E.,
Rozovsky, I.,
Trommer, B.,
Viola, K. L.,
Wals, P.,
Zhang, C.,
Finch, C. E.,
Krafft, G. A.,
and Klein, W. L.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
6448-6453[Abstract/Free Full Text]
|
| 4.
|
Hartley, D. M.,
Walsh, D. M., Ye, C. P.,
Diehl, T.,
Vasquez, S.,
Vassilev, P. M.,
Teplow, D. B.,
and Selkoe, D. J.
(1999)
J. Neurosci.
19,
8876-8884[Abstract/Free Full Text]
|
| 5.
|
Dodart, J. C.,
Mathis, C.,
and Ungerer, A.
(2000)
Rev. Neurosci.
11,
75-93[Medline]
[Order article via Infotrieve]
|
| 6.
|
Dineley, K. T.,
Westerman, M.,
Bui, D.,
Bell, K.,
Ashe, K. H.,
and Sweatt, J. D.
(2001)
J. Neurosci.
21,
4125-4133[Abstract/Free Full Text]
|
| 7.
|
Hsiao, K.,
Chapman, P.,
Nilsen, S.,
Eckman, C.,
Harigaya, Y.,
Younkin, S.,
Yang, F.,
and Cole, G.
(1996)
Science
274,
99-102[Abstract/Free Full Text]
|
| 8.
|
Atkins, C. M.,
Selcher, J. C.,
Petraitis, J. J.,
Trzaskos, J. M.,
and Sweatt, J. D.
(1998)
Nat. Neurosci.
1,
602-609[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Blum, S.,
Moore, A. N.,
Adams, F.,
and Dash, P. K.
(1999)
J. Neurosci.
19,
3535-3544[Abstract/Free Full Text]
|
| 10.
|
Selcher, J. C.,
Atkins, C. M.,
Trzaskos, J. M.,
Paylor, R.,
and Sweatt, J. D.
(1999)
Learn. Mem.
6,
478-490[Abstract/Free Full Text]
|
| 11.
|
Qian, S.,
Jiang, P.,
Guan, X. M.,
Singh, G.,
Trumbauer, M. E., Yu, H.,
Chen, H. Y.,
Van de Ploeg, L. H.,
and Zheng, H.
(1998)
Neuron
20,
611-617[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Frautschy, S. A.,
Yang, F.,
Irrizarry, M.,
Hyman, B.,
Saido, T. C.,
Hsiao, K.,
and Cole, G. M.
(1998)
Am. J. Pathol.
152,
307-317[Abstract]
|
| 13.
|
Kawarabayashi, T.,
Younkin, L. H.,
Saido, T. C.,
Shoji, M.,
Ashe, K. H.,
and Younkin, S. G.
(2001)
J. Neurosci.
21,
372-381[Abstract/Free Full Text]
|
| 14.
|
Chapman, P. F.,
White, G. L.,
Jones, M. W.,
Cooper-Blacketer, D.,
Marshall, V. J.,
Irizarry, M.,
Younkin, L.,
Good, M. A.,
Bliss, T. V.,
Hyman, B. T.,
Younkin, S. G.,
and Hsiao, K. K.
(1999)
Nat. Neurosci.
2,
271-276[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Chishti, M. A.,
Yang, D. S.,
Janus, C.,
Phinney, A. L.,
Horne, P.,
Pearson, J.,
Strome, R.,
Zuker, N.,
Loukides, J.,
French, J.,
Turner, S.,
Lozza, G.,
Grilli, M.,
Kunicki, S.,
Morissette, C.,
Paquette, J.,
Gervais, F.,
Bergeron, C.,
Fraser, P. E.,
Carlson, G. A.,
George-Hyslop, P. S.,
and Westaway, D.
(2001)
J. Biol. Chem.
276,
21562-21570[Abstract/Free Full Text]
|
| 16.
|
McNish, K. A.,
Gewirtz, J. C.,
and Davis, M.
(1997)
J. Neurosci.
17,
9353-9360[Abstract/Free Full Text]
|
| 17.
|
Maren, S.,
Aharonov, G.,
and Fanselow, M. S.
(1997)
Behav. Brain Res.
88,
261-274[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Kim, J. J.,
Rison, R. A.,
and Fanselow, M. S.
(1993)
Behav. Neurosci.
107,
1093-1098[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Kim, J. J.,
and Fanselow, M. S.
(1992)
Science
256,
675-677[Abstract/Free Full Text]
|
| 20.
|
Phillips, R. G.,
and LeDoux, J. E.
(1992)
Behav. Neurosci.
106,
274-285[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Paylor, R.,
Nguyen, M.,
Crawley, J. N.,
Patrick, J.,
Beaudet, A.,
and Orr-Urtreger, A.
(1998)
Learn. Mem.
5,
302-316[Abstract/Free Full Text]
|
| 22.
|
Borchelt, D. R.,
Ratovitski, T.,
van Lare, J.,
Lee, M. K.,
Gonzales, V.,
Jenkins, N. A.,
Copeland, N. G.,
Price, D. L.,
and Sisodia, S. S.
(1997)
Neuron
19,
939-945[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Holcomb, L.,
Gordon, M. N.,
McGowan, E., Yu, X.,
Benkovic, S.,
Jantzen, P.,
Wright, K.,
Saad, I.,
Mueller, R.,
Morgan, D.,
Sanders, S.,
Zehr, C.,
O'Campo, K.,
Hardy, J.,
Prada, C. M.,
Eckman, C.,
Younkin, S.,
Hsiao, K.,
and Duff, K.
(1998)
Nat. Med.
4,
97-100[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Butters, N.,
Granholm, E.,
Salmon, D. P.,
Grant, I.,
and Wolfe, J.
(1987)
J. Clin. Exp. Neuropsychol.
9,
479-497[Medline]
[Order article via Infotrieve]
|
| 25.
|
Welsh, K.,
Butters, N.,
Hughes, J.,
Mohs, R.,
and Heyman, A.
(1991)
Arch. Neurol.
48,
278-281[Abstract]
|
| 26.
|
Welsh, K. A.,
Butters, N.,
Hughes, J. P.,
Mohs, R. C.,
and Heyman, A.
(1992)
Arch. Neurol.
49,
448-452[Abstract]
|
| 27.
|
Deweer, B.,
Lehericy, S.,
Pillon, B.,
Baulac, M.,
Chiras, J.,
Marsault, C.,
Agid, Y.,
and Dubois, B.
(1995)
J. Neurol. Neurosurg. Psychiatry
58,
590-597[Abstract/Free Full Text]
|
| 28.
|
Fox, N. C.,
Warrington, E. K.,
Freeborough, P. A.,
Hartikainen, P.,
Kennedy, A. M.,
Stevens, J. M.,
and Rossor, M. N.
(1996)
Brain
119,
2001-2007[Abstract/Free Full Text]
|
| 29.
|
Fox, N. C.,
Warrington, E. K.,
Stevens, J. M.,
and Rossor, M. N.
(1996)
Ann. N. Y. Acad. Sci.
777,
226-232[Medline]
[Order article via Infotrieve]
|
| 30.
|
Marks, M. J.,
Burch, J. B.,
and Collins, A. C.
(1983)
J. Pharmacol. Exp. Ther.
226,
817-825[Free Full Text]
|
| 31.
|
Ke, L.,
Eisenhour, C. M.,
Bencherif, M.,
and Lukas, R. J.
(1998)
J. Pharmacol. Exp. Ther.
286,
825-840[Abstract/Free Full Text]
|
| 32.
|
Fenster, C. P.,
Hicks, J. H.,
Beckman, M. L.,
Covernton, P. J.,
Quick, M. W.,
and Lester, R. A.
(1999)
Ann. N. Y. Acad. Sci.
868,
620-623[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Buisson, B.,
and Bertrand, D.
(2001)
J. Neurosci.
21,
1819-1829[Abstract/Free Full Text]
|
| 34.
|
Schafe, G. E.,
Nadel, N. V.,
Sullivan, G. M.,
Harris, A.,
and LeDoux, J. E.
(1999)
Learn. Mem.
6,
97-110[Abstract/Free Full Text]
|
| 35.
|
Koistinaho, M.,
Ort, M.,
Cimadevilla, J. M.,
Vondrous, R.,
Cordell, B.,
Koistinaho, J.,
Bures, J.,
and Higgins, L. S.
(2001)
Proc. Nat. Acad. Sci., U. S. A.
98,
14675-14680[Abstract/Free Full Text]
|
| 36.
|
Westerman, M. A.,
Cooper-Blacketer, D.,
Mariash, A.,
Kotilinek, L.,
Kawarabayashi, T.,
Younkin, L. H.,
Carlson, G. A.,
Younkin, S. G.,
and Ashe, K. H.
(2002)
J. Neurosci.
22,
1858-1867[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg